The board of directors of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. announce that, the Company has received the Notification of Approval for Supplementary Drug Application (notification No.: 2023B05505) of the quality and efficacy consistency evaluation of generic drugs for chemical injection (the ?Consistency Evaluation?) issued by the National Medical Products Administration of the PRC (the ?NMPA?). The Consistency Evaluation application for Doxorubicin Hydrochloride Liposome Injection (LIBOd®,) (the ?Drug?) has been passed. Relevant information is as follows: Drug name: Doxorubicin Hydrochloride Liposome Injection; Specifications: 10ml:20mg; Application matter: The quality and efficacy consistency evaluation of generic drugs; Registration type: Class 6 generic drug (2007); Acceptance No.: CYHB2250452; Original drug approval number: NMPN- H2 0084432; Applicant: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.

Ltd. LIBOd® (®) from Nano- drug platform of the Company for the treatment of tumors, the first generic drug from Doxil® in China and the first generic drug of nanomedicine at home and abroad, was launched for sale in August 2009 and it obtained favorable market response and reputation. The Drug is a new doxorubicin formula which adopts the advanced stealth liposomal encapsulation technology and has passive targeting characteristics. The Drug is a new generation of replacement for anthracycline drugs.

In oncology, it has the advantages of enhancing efficacy and remarkably lowering the effects of cardiac toxicity, myelosuppression and hair-loss. The Drug is used for the treatment of AIDS-relating Kaposi's sarcoma, multiple myeloma, breast cancer and ovarian cancer, etc. According to relevant policies and regulations, medical institutions have the opportunity to prioritize the procurement and clinical selection of drug varieties that have passed the Consistency Evaluation.

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, and the influence of relevant policies, market environment and other factors, there are uncertainties in drug research and development. Investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively facilitate the further related work of the Consistency Evaluation and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict accordance with relevant regulations.